Fingolimod

Type: Keyphrase

Name: Fingolimod

First reported Jun 14 2013 - Updated Jun 14 2013 - 1 reports

Rebranding MS as a dementia: part 2

"What do you think of this of short animation? It tries to explain the impact of MS on the brain; in the other words the early phases of MS Dementia." Disclaimer : This animation is part of a series of animations on a MSer website, called " MS and Our ... [Published Multiple Sclerosis Research - Jun 14 2013]

Entities: Novartis AG, Fingolimod, Gilenya, Dementia

First reported Jun 14 2013 - Updated Jun 14 2013 - 1 reports

Scripps Research Institute

Findings on Multiple Sclerosis Discussed by Investigators at Scripps Research Institute

(NewsRx) -- By a News Reporter-Staff News Editor at Immunotherapy Weekly -- Data detailed on Autoimmune Diseases and Disorders have been presented. According to news reporting from La Jolla, California, by NewsRx journalists, research stated, "Fingolimod ... [Published NewsRX - Jun 14 2013]

Entities: Scripps Research Institute, Multiple Sclerosis, Fingolimod, Receptor

First reported Jun 12 2013 - Updated Jun 12 2013 - 1 reports

Switching To Gilenya® (Fingolimod) From Standard Interferon Offers Sustained Freedom From Disease Activity For People With Relapsing Remitting MS

Two new analyses from the pivotal Phase III TRANSFORMS study presented at the European Neurological Society (ENS) have shown early and sustained improvements in disease activity in patients who were switched from an interferon to Gilenya® (fingolimod). ... [Published MS News - Jun 12 2013]

Entities: Fingolimod, Gilenya, Freedom From, Interferon

First reported Jun 10 2013 - Updated Jun 11 2013 - 1 reports

European Stocks Seen Lower On China Concerns

European stocks are seen opening lower on Monday as optimism about the U.S. economy gives way to anxiety over China's future growth. A slew of Chinese data released over the weakened pointed to sluggish activity in the world's second largest economy. ... [Published RTTNews.com - Jun 10 2013]

Entities: China, Sentix Investor Confidence, Index

First reported Jun 10 2013 - Updated Jun 10 2013 - 1 reports

Data Shows Switching MS Patients from Interferon to Gilenya Dramatically Reduces Disease Activity

Two analyses of data from pivotal trials have found that switching relapsing-remitting multiple sclerosis (MS) patients over from interferon therapy to Novartis’s once-daily pill Gilenya™ (fingolimid) leads to a 50% increase in the proportion of patients ... [Published Pharma-Mag - Jun 10 2013]

Entities: Gilenya, Interferon, Multiple Sclerosis, Fingolimod, Patient

First reported Jun 10 2013 - Updated Jun 10 2013 - 1 reports

The Swiss Market Finished Little Changed Monday

The Swiss stock market ended Monday's session with a slight gain. The market received a boost from the upward revision to the first quarter Japanese GDP result, but was also negatively impacted by some weak economic data from China.The May jobs report ... [Published RTTNews.com - Jun 10 2013]

Entities: Market, Index, Fingolimod

First reported Jun 10 2013 - Updated Jun 10 2013 - 1 reports

'First pill for MS' continues to impress experts

A PILL for multiple sclerosis first trialled in the North-East is proving to be a major advance in the treatment of the disease.Patients at the Royal Victoria Infirmary in Newcastle have been on the new drug fingolimod for years, after being one of four ... [Published Northern Echo - Jun 10 2013]

Entities: Fingolimod, Multiple Sclerosis, Patient, Multiple Sclerosis Therapy, Interferon

First reported Jun 07 2013 - Updated Jun 07 2013 - 1 reports

Should natalizumab be first-line in JC virus negative MSers? The data says yes.

After Prof G's recent post about about whether Natalizumab (Tysabri) will get a first line licence , this new work is interesting Campbell et al. Comparative effectiveness of early Natalizumab treatment in JC virus-negative relapsing-remitting multiple ... [Published Multiple Sclerosis Research - Jun 07 2013]

Entities: natalizumab, JC Virus, Fingolimod

First reported Jun 05 2013 - Updated Jun 05 2013 - 1 reports

New data at ENS show Novartis drug Gilenya benefited patients by improving all four key measures of multiple sclerosis

Today 1:17 AM ET (Thomson Reuters ONE)Novartis International AG / . Processed and transmitted by Thomson Reuters ONE. The issuer is solely responsible for the content of this announcement.- Gilenya improved the key measures: brain volume loss, MRI lesion ... [Published TD Ameritrade - Jun 05 2013]

Entities: Gilenya, Multiple Sclerosis, Fingolimod, Novartis AG, European Neurological Society

First reported May 30 2013 - Updated May 30 2013 - 1 reports

Reduction of the washout time between natalizumab and fingolimod

[Published Multiple Sclerosis Journal RSS feed -- OnlineFi ... - May 30 2013]

Entities: Fingolimod, natalizumab

First reported May 21 2013 - Updated May 21 2013 - 2 reports

Frequent early multiple sclerosis relapses during treatment with fingolimod: a paradoxical effect?

[Published Multiple Sclerosis Journal RSS feed -- OnlineFi ... - May 21 2013]

Entities: Fingolimod, Multiple Sclerosis

First reported Apr 11 2013 - Updated Apr 12 2013 - 1 reports

Human medicines European Public Assessment Report (EPAR): Gilenya, fingolimod, Revision: 4, Authorised

[Published Pending EC decisions and European Public Assess ... - Apr 11 2013]

Entities: Gilenya, Fingolimod

Quotes

"The good news is that Siponimod is currently being tested in SPMS. The trial programme is trying to address the needs of SPMSers. I think this study have more than a 50% chance of being positive."

Phase 2 siponimod trial results [Published Multiple Sclerosis Research - Jun 18 2013]

..." Disclaimer : This animation is part of a series of animations on a MSer website, called " MS and Our Story "; I note the site is sponsored by Novartis. Novartis are a Pharma Company that produce and market a drug called Gilenya (Fingolimod) that is licensed to treat relapsing forms of MS. " Should we rebrand MS as dementia? Have your say? "

Rebranding MS as a dementia: part 2 [Published Multiple Sclerosis Research - Jun 14 2013]

...According to news reporting from La Jolla, California, by NewsRx journalists, research stated, "Fingolimod is the first oral disease-modifying therapy approved for relapsing forms of multiple sclerosis MS). Following phosphorylation in vivo, the active agent, fingolimod phosphate (fingolimod-P), acts as a sphingosine 1-phosphate (S1P) receptor modulator, binding with high affinity to four of the five known S1P receptors (S1P(1), S1P(3), S1P(4) and S1P(5))."

Findings on Multiple Sclerosis Discussed by Investigators at Scripps Research Institute [Published NewsRX - Jun 14 2013]

"In the current environment it is essential that euro area governments continue their reform efforts, individually and jointly, keeping in mind the need to curtail rent-seeking behaviour and protect the weakest in society" he said

European Markets Finished Mixed After Weak Chinese Data [Published RTTNews.com - Jun 10 2013]

More Content

sort by: Date \| Relevance
Use of Natalizumab in Patients with Active Rela... [Published Sexual Development - Jun 18 2013]
Phase 2 siponimod trial results [Published Multiple Sclerosis Research - Jun 18 2013]
Biogen Idec Inc. (BIIB), Sanofi SA (ADR) (SNY):... [Published InsiderMonkey.com - Jun 17 2013]
A Must Have Pharma Stock [Published Motley Fool - Jun 14 2013]
Rebranding MS as a dementia: part 2 [Published Multiple Sclerosis Research - Jun 14 2013]
Findings on Multiple Sclerosis Discussed by Inv... [Published NewsRX - Jun 14 2013]
Switching To Gilenya® (Fingolimod) From Standar... [Published MS News - Jun 12 2013]
The Swiss Market Finished Little Changed Monday [Published RTTNews.com - Jun 10 2013]
European Markets Finished Mixed After Weak Chin... [Published RTTNews.com - Jun 10 2013]
'First pill for MS' continues to impress experts [Published Northern Echo - Jun 10 2013]
Data Shows Switching MS Patients from Interfero... [Published Pharma-Mag - Jun 10 2013]
European Stocks Seen Lower On China Concerns [Published RTTNews.com - Jun 10 2013]
Novartis: Gilenya Effective Against 4 Measures ... [Published RTTNews.com - Jun 10 2013]
Should natalizumab be first-line in JC virus ne... [Published Multiple Sclerosis Research - Jun 07 2013]
New Multiple Sclerosis Treatment Promises Uniqu... [Published EMax Health - Jun 07 2013]
New data at ENS show Novartis drug Gilenya bene... [Published FiercePharma - Jun 05 2013]
New data shows Novartis MS drug improves four k... [Published Pharmaceutical Technology - Jun 05 2013]
New data at ENS show Novartis drug Gilenya bene... [Published TD Ameritrade - Jun 05 2013]
Study Hints of Rituximab MS Benefit (CME/CE) [Published MedPage Today - Jun 03 2013]
Medicines Safety Update, Volume 4, Number 3, Ju... [Published Australian Dept. of Health - Jun 03 2013]
Promoting Remyelination in Multiple Sclerosis –... [Published Brain Blogger - Jun 02 2013]
MRI Findings Drive Tx Changes in MS [Published MedPage Today - May 31 2013]
Opinion/decision on a Paediatric Investigation ... [Published Opinion/decision on a Paediatric Investigation ... - May 31 2013]
Biogen Idec says Tecfidera launch delayed in Eu... [Published PMLive - May 31 2013]
Sphingosine 1-Phosphate in Renal Diseases [Published Sexual Development - May 31 2013]
Novartis' Multichannel Campaign is Frontrunner ... [Published eyeforpharma.com - May 30 2013]
Reduction of the washout time between natalizum... [Published Multiple Sclerosis Journal RSS feed -- OnlineFi ... - May 30 2013]
Relapsing MS patients more satisfied with Novar... [Published Yahoo! Finance - May 30 2013]
Relapsing MS patients more satisfied with Novar... [Published PR Newswire: General Business - May 30 2013]
Novartis launches new campaign to raise awarene... [Published PharmaBiz - May 29 2013]